Follow The Filings

PRCT Procept Biorobotics Corporation

Health Care, filed as PROCEPT BIOROBOTICS CORP (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.5%
  • $2.7M

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 0.52%

Who owns PRCT

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.52% Hold 120,000 $2.7M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PRCT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PRCT insider trades
  • $11M bought by 2 insiders
  • None no sales outside a trading plan
  • $222K sold by 1 insider under 10b5-1 plans
  1. Larry L Wood CEO
    Buy
    $498K 23,900 shares at $20.85 New stake
    Traded Aug 7 Filed Aug 10
    ↗
  2. Alaleh Nouri EVP, CLO, Corp. Sec.
    Planned sale
    $139K 5,363 shares at $25.96 4.8% of stake
    Traded Mar 19 Filed Mar 19
    ↗
  3. Alaleh Nouri EVP, CLO, Corp. Sec.
    Planned sale
    $83K 3,243 shares at $25.65 2.8% of stake
    Traded Mar 10 Filed Mar 12
    ↗
  4. Antal Rohit Desai Director
    Buy
    $10.5M 426,262 shares at $24.59 New stake
    Traded Mar 5–9 Filed Mar 9
    ↗

Also filed in the last 12 months, not counted as buying or selling: 19 stock grants and 10 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
8-K 1.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $136.19M $224.5M $308.05M
Gross profit $71.05M $137.1M $196.23M
Gross margin * 52.2% 61.1% 63.7%
Net income -$105.9M -$91.41M -$95.57M
Net margin * -77.8% -40.7% -31.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $350.57M $481.84M $450.38M
Total non-current assets * $54.15M $52.18M $57.7M
Total assets $404.72M $534.02M $508.08M
Total current liabilities $45.93M $53.13M $65.8M
Total non-current liabilities * $78.04M $78.66M $76.42M
Total equity $280.75M $402.22M $365.87M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$108M -$99.21M -$48.98M
Cash from investing -$25.21M -$4.41M -$9.36M
Cash from financing $167.8M $180.12M $11.19M
Net change in cash $34.59M $76.5M -$47.22M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.